Metformin, a first-line agent for the treatment of type 2 diabetes, improves upper small intestine microbiota composition and restores the sodium-glucose cotransporter-1 (SGLT1)-dependent glucose sensing to regulate glucose homeostasis (Wu et al., 2017; Bauer et al., 2018). Here, SLC5A1 is linked to type 2 diabetes mellitus.